Limited Asian Fallout From Pfizer-Allergan Merger?
This article was originally published in PharmAsia News
As far as Asian and emerging pharma markets go, it is clear that Pfizer will be the dominant partner in the planned $160bn merger with Allergan. The US firm has a broad reach in these areas that Allergan will be looking to tap into, and major restructuring in big regional markets such as China and Japan looks unlikely.
You may also be interested in...
Regardless of who wins, China seems to be looking beyond the 3 November US General Election, instead pouring in large resources to elevate its domestic health sector on a par with international standards, creating opportunities and profoundly impacting many areas from novel therapy development to investment decisions.
While it has raised the full-year profit outlook, Takeda came in under analysts' consensus for some of its fiscal first-half figures, pointing to a growing forex impact.
As the China immuno-oncology sector becomes increasingly crowded, CStone teams up with an innovative US business partner to go global.